Drugs / 609A
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03950297 | May 2019 → Oct 2020 | cancer | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05193214 | Jan 2022 → Dec 2023 | soft tissue sarcoma | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05138146 | Dec 2021 → Nov 2023 | soft tissue sarcoma | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03998345 | Jul → Dec 2020 | cancer | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 609A | “Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A)” NCT05193214 ↗ |
| Action | Inhibit | “anti-PD-1” NCT05138146 ↗ |
| Modality | Monoclonal antibody | “609A, a recombinant monoclonal anti-PD-1 antibody product” NCT03950297 ↗ |
| Route | Intravenous | “Dose 1 mg/kg, Q3W, IV.” NCT03950297 ↗ |